Secondary prophylactic treatment with tacrolimus 0.1% ointment is more effective, leads to cost savings and higher QoL in comparison to standard tacrolimus 0.1% ointment use, especially in patients with severe AD.
COST COMPARISON BETWEEN TWO ANTI-TUMOR NECROSIS FACTOR (ANTI-TNF) THERAPIES IN PATIENTS WITH PSORIASIS USING AVERAGE SALES PRICE
Tang B, Rahman MI, Thompson HC, Hilliard R, Naim A, Dabbous O Centocor, Inc, Horsham, PA, USA OBJECTIVES: To compare annual costs of anti-TNF therapies in patients with psoriasis (PsO). METHODS: A decision-model was created using TreeAge software, with clinical trial data and average sales price (ASP) +6% (2Q 2007) for drug costs. Two treatment strategies were compared: etanercept first then switching to infliximab and infliximab first then switching to etanercept. The model assumed patients who failed to achieve Psoriasis Area and Severity Index (PASI)-50 would switch to the other biologic after 24 weeks. The efficacy rates after switching were assumed to be the same as the first-line treatment. A sensitivity analysis reducing the efficacy rates after switching by 10%-30% was conducted. The cost of adverse events was not included in the model. Infusion fees ($237.92/infusion-2Q 2007) were included for infliximab. RESULTS: With infliximab, 90% of patients achieved PASI-50 at week-24 and continued receiving infliximab. Patients (10%) who failed to achieve PASI-50 were switched to etanercept. With etanercept, 77% of patients achieved PASI-50 at week-24 and continued etanercept treatment. Patients (23%) who failed to achieve PASI-50 were switched to infliximab. The etanercept-first strategy costs $22,113 annually and results in an overall efficacy rate of 78.5% and a cost-efficacy (CE) of $28,171. The infliximab-first strategy costs $23,544 annually and results in an 89.4% efficacy rate and a CE of $26,351. Compared with etanercept, the infliximab-first strategy costs $1820 less per PASI-50 response. The incremental CE ratio per PASI-50 was $13,190. The sensitivity analysis indicated that the results are robust and in the same direction as the original assumption. CONCLUSION: This decision model demonstrates that an infliximab-first strategy is more cost-effective than an etanercept-first strategy in the treatment of psoriasis.
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